<DOC>
	<DOCNO>NCT01817699</DOCNO>
	<brief_summary>The purpose study evaluate effect anemia correction vitamin D supplementation kidney transplant recipient .</brief_summary>
	<brief_title>Correcting Anemia Native Vitamin D Supplementation Kidney Transplant Recipients</brief_title>
	<detailed_description>Sample size estimation : The previous trial ( CAPRIT study ) show 2.0 g/dL increase hemoglobin ( Hb ) reduce 69 % 2-year decline estimate glomerular filtration rate ( eGFR ) ( Choukroun G , et al . J Am Soc Nephrol , 2012 ) . Given annual eGFR decline patient Hb level &lt; 10.5 g/dL 1.66 ( SD , 2.47 ) mL/min per 1.73 m2 , investigator hypothesize 2-year eGFR decline conservative anemia management group aggressive anemia correction group 3.32 ( SD , 4.94 ) 1.03 ( SD , 4.94 ) mL/min per 1.73 m2 , respectively . Assuming 20 % dropout lost-to-follow , planned sample size 246 patient would yield power 90 % group comparison use t-test type I error 5 % . Regarding cholecalciferol supplementation , 1,000 IU/day would increase serum 25-hydroxyvitamin D level 11.8 ng/mL patient BMI &lt; 30 , suggest previous trial ( Gallagher JC , et al . Ann Intern Med , 2012 ) . The investigator find prospective cohort study 98.2 % Japanese kidney transplant recipient BMI &lt; 30 , 10 ng/mL increase 25-hydroxyvitamin D level significantly associate 0.75 mL/min/1.73 m2 less decrease annual eGFR change independent potential confounders ( submission ) . Therefore , investigator expect 1.77 mL/min per 1.73 m2 eGFR would preserve 1,000 IU/day cholecalciferol supplementation 2 year . Based assumption , study size provide power 70 % . Estimating kidney function : In primary analysis , eGFR calculate use Japanese equation sample size calculation ( Matsuo S , et al . Am J Kidney Dis , 2009 ) . However , formula yet validate kidney transplant recipient . Therefore , investigator use creatinine-based CKD-EPI equation Japanese coefficient ( Stevens LA , et al . Nephrol Dial Transplant , 2010 . Horio M , et al . Am J Kidney Dis , 2010 ) available formula validate Japanese kidney transplant recipient time analysis . Statistical analysis : For group comparison primary analysis , investigator use t-test Wilcoxon rank sum test accord distribution eGFR change . In analysis , analyze time course eGFR respect treatment assignment , change eGFR time analyze linear mixed model repeat measure fix random intercept slope . The multivariate model contain time-varying eGFR dependent variable treatment group well number measurement ( time ) independent variable . The study hypothesis test add appropriate interaction term exposures time . For secondary endpoint , investigator use t-test , Wilcoxon rank sum test , log-rank test group comparison , generalize linear model Cox proportional hazard model estimate effect intervention , appropriately . The investigator also adjust baseline level past history outcome . Other potential confounders , age , sex , time since transplantation , blood pressure , urinary protein level , diabetes , adjust sensitivity analysis . The interaction check anemia management cholecalciferol supplementation well intervention baseline level urinary protein , eGFR , Hb , 25-hydroxyvitamin D , use active vitamin D compound , length time since transplantation . Additionally , stratify analysis conduct accord 0.2 g/g･creatinine urinary protein date transplantation ( November 1999 , release date mycophenolate mofetil Japan ) . However , study size large enough statistically evaluate interaction . The result analysis interpreted caution regard exploratory hypothesis generate . Missing value : Missing value impute primary analysis . In sensitivity analysis , investigator use multiple imputation method last-observation-carried-forward method .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>≥15 &lt; 60 ml/min per 1.73 m2 estimate glomerular filtration rate Transplanted allograft kidney least 1 year &lt; 10.5 g/dL Hb without iron deficiency ( serum ferritin level ≥50 ng/ml ) erythropoiesis stimulate agent treatment regardless iron status With write informed consent On anticancer treatment History ischemic stroke transient ischemic attack Corrected serum calcium ≥10.5 mg/dL HIV virus infection Anticipated refractory hypertension use epoetin beta pegol In pregnancy lactation Current use native vitamin D supplement Patients ineligible accord investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cholecalciferol</keyword>
	<keyword>Methoxy polyethylene glycol-epoetin beta</keyword>
	<keyword>Hematinics</keyword>
	<keyword>Bone Diseases , Metabolic</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Graft Rejection</keyword>
</DOC>